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ABSTRACT 
Objectives: The aim of this work was to study the prevalence 
of anti-Trypanosoma cruzi in the blood donor population in 
Buenos Aires, to compare the relative sensitivity and specificity 
of the two screening tests used and to confirm the results with 
a third assay. 
Material and Methods: Between May 1995 and July 1999, 
64,887 blood donor consecutive samples were screened with 
the following commercial tests: indirect hemagglutination (IHA) 
(Polychaco, Buenos Aires, Argentina) and enzyme-linked 
immunosorbent assay (ELISA) (40,222 with Chagatek, Organon 
Teknika, Buenos Aires, Argentina, and 24,665 with Chagas 
EIA, Abbott, Sao Paulo, Brazil). Repeatedly reactive samples in 
one or both tests were analyzed with a third method: dot blot 
(Bio Chagas, Gador, Buenos Aires, Argentina) or particle agglu- 
tination (Serodia, Fujirebio, Tokyo, Japan). Sera that reacted in 
at least two tests were considered positive. 
Results: The seroprevalence was 2.66% (1744 samples were 
reactive for one or both screening tests), and 1.46% (949 sam- 
ples) were confirmed positive. The ELlSAs proved to be more 
sensitive (relative sensitivity: 99.67-99.71%), whereas 192 sam- 
ples (0.47%) were IHA false-negatives (relative sensitivity: 
79.77%). Relative specificity for EIA was 98.47-99.23% and for 
IHA 99.85%. 
Conclusions: Results suggest the need of performing two 
screening tests for Chagas disease in blood banks from 
endemic areas and the importance of a third confirmatory assay 
to avoid unnecessary medical counseling. 
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Chagas disease is endemic in Latin America. Its agent, 
Trypanosoma cruzi, is transmitted mainly through the 
feces of infected triatomid bugs. Once infection occurs, 
the parasite may produce an acute disease, that will nat- 
urally resolve, and the infected host will remain asymp- 
tomatic for decades before chronic manifestations 
emerge. ’ 
Blood transfusion is the second most common means 
of infection in endemic areas.2,3 The risk of infection via 
transfusion of a contaminated blood unit is in the range 
of 12% to 250/o.* Consequently, the challenge for blood 
banks is to identify and exclude chronic, asymptomatic 
carriers of the parasite without negatively affecting the 
blood supply. 
In Latin America, the prevalence of Ecruzi-infected 
blood in blood banks is as high as 62% in Bolivia and 
around 2 to 3% in major cities like Caracas, Venezuela, and 
Buenos Aires, Argentina.* 
Current methods for diagnosing I;cruzi infection are 
based on detection of antibodies to the parasite, because 
conventional parasitologic methods are difficult to per- 
form and have a sensitivity of 30 to 50%.5 Because none 
of the available test kits for detecting antibodies to 
T.cruzi is highly sensitive,’ it has been mandated in 
Argentina that all blood donations must be screened by 
two assays based on different methods or different anti- 
gen preparations. 
The assays are not sufficiently specific, especially in 
areas of low prevalence of infection.’ This is primarily 
because the antigen preparations currently employed are 
derived from parasite extracts and contain epitopes that 
may be detected by serum antibodies of patients with 
other infections.“J 
The sensitivity and specificity of serologic tests are 
high when evaluated with well-characterized sera, com- 
pared with negative serum from persons with no history 
of exposure to the Chagas parasite. However, when com- 
binations of serologic tests are used on samples obtained 
from epidemiologic surveys or blood bank screening in 
endemic areas, discrepant results are commonly 
detected.“‘” Consequently, the Pan American Health 
Organization suggests the use of at least two methods 
for the diagnosis of the disease.’ 
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Table 1. Reactivity for Chagas Disease in Each Test or Combination of Tests among 64,887 Blood Units 
Group A Group B 
Pattern Number 
(Assay) Number (%) DS/Co’ < 2 (%j Number (%) DS/CO < 2 (%j 








(EIA+IHA) 28 (0.070) 18 (64.0) 16 (0.006) 
4 (EIA+Srd) 138 (0.340) 
IO (62.5) 
105 (76.1) 54 (0.220) 37 
5 (IHA+3rd) (0.005) 
(68.5) 
2 1 (0.004) 
6 (EIA+IHA+3rd) 436 (1.080) 67 (15.4) 274 (1 .I IO) 22 (8.0) 
DSKO = donor sample optical density/cutoff optical density. 
The goal of this work was to study the prevalence of 
anti-Z cruzi in the blood donor population, to compare 
the relative sensitivity and specil?city of the two screen- 
ing tests used, and to confirm the results with a third 
assay. 
MATERIALS AND METHODS 
Study Population 
Between May 1995 and July 1999,64,887 consecutive 
volunteer blood donors were studied. 
Serologic Tests 
Donations were screened with two commercial tests: 
1. Indirect hemagglutination assay (IHA) (Polychaco, 
Buenos Aires, Argentina) and 
2. Enzyme-linked immunosorbent assay (ELISA) (40,222 
with Chagatek, Organon Teknika, Buenos Aires, 
Argentina: group A; 24,665 with Chagas EIA, Abbott, 
SPo Paulo, Brazil: group B). The presence of antibody 
to 7: cruzi was determined by relating the optical 
density (OD) of the specimen to the cutoff value 
(donor sample OD/cutoff OD). 
Each assay was performed according to the respec- 
tive manufacturer’s instructions. 
All initially reactive samples were tested again. If a 
sample was repeatably reactive (RR) in any of the tests, 
the unit was discarded and the sample was assayed with 
a third method: 
1. Dot blot (DB) (Bio Chagas, Gador, Buenos Aires, 
Argentina) which uses recombinant antigens. This 
EL4 is carried out on test strips consisting of a plas- 
tic backing covered with a nitrocellulose membrane 
to which a mixture of T. cruzi antigens has been 
applied as a horizontal line. This test has shown a 
sensitivity of 99.6% when tested with samples IHA-, 
immunofluorescent assay (IFA) and enzyme 
immunoassay Opositive (299 of 300 samples) and 
a specificity of 99.1% (347/350 samples),” or 
2. Particle agglutination (PA) (Serodia, Fujirebio, Tokyo, 
Japan), which uses gelatin particle carriers . 
Sera that reacted in at least two tests were considered 
positive and when reacted in only one test were con- 
sidered discordant. 
Statistical Analysis 
Seroprevalence percentages were calculated as the 
mean, standard error (SE), and confidence interval (CI) 
at 95%. 
RESULTS 
The seroprevalence was 2.66% (1,728/64,887 samples 
were reactive for one or both screening tests, SE = 0.0685, 
CI = 2.185-2.566; P c 0.05) and 1.46% (949/64,887 sera 
that reacted in at least 2 of 3 tests, SE = 0.0471; CI = 
1.5578-1.8780; P c 0.05) were confiied positive. There 
were six groups with different patterns (Table 1). 
The sera considered positive (at least 2 of 3 assays 
reactive) were: 44 samples (0.07%) from pattern 3 (EIA 
and IHA reactive), 192 samples (0.29%) from pattern 4 
(EIA and third assay reactive), 3 samples (0.0046%) from 
pattern 5 (IHA and third assay reactive), and 710 sam- 
ples (1.09%) from pattern 6 (EIA, IHA, and third assay 
reactive). 
It is remarkable that 525 of 685 samples in pattern 
1 (false-positive EIA) had a weak EL4 result (donor sam- 
ple OD/cutoff OD < 2). The percentages are 94% (292 
samples) and 61.8% (233 samples) for EIA in group A 
and B (Organon and Abbott), respectively. In pattern 3 
(false-negative third assay) 28 samples (63.63%) and in 
pattern 4 (false-negative II-IA) 142 samples (73.9%) had 
a weak result. On the other hand, in pattern 6 (three 
assays reactive) 62 1 samples (87.46%) had an EIA strong 
result (donor sample OD/cutoff OD > 2). 
As shown in Table 2, both EIAs proved to be more 
sensitive (99.67% and 99.71% relative sensitivity for tests 
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Table 2. Diagnostic Performance of the Three Assays Used To Screen Donated Blood Samples 
Reactive Confirmed Positive* False Negative False Positive Relative Sensitivity Relative Specificity 
EIA (A) 910 602 2 308 99.67 99.23 
EIA (B) 721 344 1 377 99.71 98.47 
IHA 851 757 192 94 79.77 99.85 
*At least 2 of 3 tests reactive. 
A and B, respectively) in the studied blood donor popu- 
lation, whereas 192 samples were IHA false-negative 
(79.77% relative sensitivity). The relative specificity results 
were 99.23%, 98.470/o, and 99.85% for EL4 test A, EIA test 
B, and IHA, respectively. 
DISCUSSION 
Serologic tests are the most reliable and practical proce- 
dures for identifying chronically Chagas disease-infected 
individuals. In general, the sensitivities and specificities of 
the commercial serologic tests for 7: cruzi are high when 
they are evaluated with well-characterized sent, but dis- 
crepancies are common when combinations of serologic 
tests are used in epidemiologic surveys or blood bank 
screening.6j7,‘2 
In the particular case of Chagas disease, no serologic 
gold standard for the definition of the disease exists, since 
cross-reactivity of 1: cruzi antigens with antibodies raised 
against other coendemic parasites (Leishmaniu and Try 
panosoma rangeli) is frequent.‘” 
None of the methods for diagnosis of Chagas disease 
can be regarded as 100% safe in blood bank screenings. 
Furthermore, with the low prevalence of infected donors, 
one has to expect low positive predictive values, leading 
to a high false-positive rate of results that must be con- 
firmed by other methods.‘” Contradictory results have 
been obtained by different methods and laboratories, 
probably owing to the use of different strains of T. crud 
and different antigenic fractions and procedures, causing 
variations in sensitivity and specificity.15 
The prevalence of blood donors with anti-l: cruzi at 
the blood bank was 2.66%. Of all tested sera, 1.09% were 
positive in the three tests, 0.37% in two tests, and a 1.2% 
reacted in only one test. That means that the confirmed 
seroprevalence is 1.46% (at least 2 tests reactive). 
The seroprevalence obtained in our blood bank ser- 
vice is lower than that reported by Schmuilis and col- 
leagues.16 They have reported a 3.6 to 4.9% incidence of 
positive donors between 1995 and 1997 in Argentina. 
The reason for this discrepancy could be the different 
blood donor populations. They have analyzed the data 
from the whole country, including rural and urban areas, 
and the majority of the blood donors who donate in our 
service live in Buenos Aires, a major city. 
Both EIAs were more sensitive but less specific than 
IHA. Other studies reported satisfactory results in the rel- 
ative sensitivities and specificities from different com- 
mercial EIAs and a lower sensitivity for IHA. ‘“J~J’.” 
Saez-Alquezar et al, evaluating the performance of 
Brazilian blood banks in testing for Chagas disease, 
noted that 42.1% of the enrolled blood banks reported 
errors, showing that the use of more than one tech- 
nique is still necessary in the screening of anti-Z crud. 
Blood banks using only IHA were responsible for 49 of 
the 64 errors, which would imply that this assay has a 
low performance. lY 
The ideal diagnostic test must have high sensitivity 
and high specificity. In most cases, however, increased 
sensitivity can be obtained at the expense of specificity, 
leading to an increased proportion of false-positive 
results, as occurred with both EIAs used in the present 
study. 
Other authors have described a variable number of 
cases reacting at about the cutoff value for positivity in 
the presently used serologic tests.20 In the present study, 
results show that one could predict a false-positive result 
if the OD value is low and the sample is reactive in one 
test. 
Owing to socioeconomic factors, the migration of 
infected people from the areas in which the disease is 
endemic to the urban centers is frequent, and blood trans- 
fusion has become an important means of infection.‘3 
The intensive immigration to the United States, Canada, 
Europe, and Australia opened the possibility of Chagas 
disease spreading to new frontiers. In fact, there are sev- 
eral reports of transfusion-transmitted Chagas in North 
America and Europe.21-2” Furthermore, since Chagas dis- 
ease is usually asymptomatic and rarely recognized by 
American and European physicians, other transfusion- 
related cases may have occurred and not been detected. 
Several studies have reported the presence of serologic 
markers for 7: cruzi in Latin American immigrants in the 
United States and Europe25,26; and recent papers have 
determined that the seroprevalence of I: cruzi in Amer- 
ican blood donor populations with lower levels of risk 
ranges from 0.01% to 0.2%.1”~2’~2s These studies primarily 
involved populations with high numbers of at-risk blood 
donors, but it was also reported that blood donors 
seropositive for T. cruzi are present in populations with 
low to moderate risk.29 
92 International Journal of Infectious Diseases / Volume 5, Number 2.2001 
Blood screening has not been implemented in the 
United States, in part because no test for blood bank 
screening has been licensed by the U.S. Food and Drug 
Administration (FDA). Many sensitive and specific assays 
have been described, such as radioimmunoprecipitation 
assay (RIPA), polymemse chain reaction (PCR), and chemi- 
luminescent EL4,3o-33 which have been shown to be sen- 
sitive but are not feasible for blood bank screening. 
Recently, it has been reported that a new immunoblot 
assay, INNO-LIA, is a reliable assay for the serologic con- 
firmation of Chagas disease, showing a specificity of 98. I 
to 99.3% and a sensitivity of 99.4 to 1OO%.34,35 
Results of the present study suggest the need of per- 
forming two screening tests for Chagas disease in blood 
banks from endemic areas and the importance of a third 
confirmatory assay to avoid unnecessary medical coun- 
seling. In countries with a low prevalence of anti-l: cruzi, 
like the United States, an initial screening identification 
of T. cruzi-positive donors with an EIA could be used 
along with a supplemental or confirmatory test, includ- 
ing PCR, Western blot, RIPA, or LIA to allow the reentry 
of initially false-positive blood donors. 
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Correction 
Changes over Time in the Epidemiology of Diarrhea and Malnutrition among Children in an 
Urban Brazilian Shantytown, 1989 to 1996 
In International Journal of Infectious Diseases Volume 4, Number 4,200O “Changes over Time in the Epidemiology 
of Diarrhea and Malnutrition among Children in an Urban Brazilian Shantytown, 1989 to 1996” by Sean R. Moore, MS; 
AIdo A. M. Lima, MD, PhD; John B. Schorling, MD; Manuel S. Barboza Jr, MD; Albert0 M. Soares, PhD; and Richard L. Guer- 
rant, MD, page 179, the first sentence of the results section of the abstract should have read as follows; please note 
these changes in your copy. 
Results: Declines in both age-adjusted attack rates (6.0 
episodes/child-year in study year 3 [I9911 to 2.5 episodes 
per child-year in study year 8 [1996]) and days of diarrhea per 
child-year (30.8 days/child-year in year 3 to 8.5 days/child- 
year in year 8) were correlated with yearly improvements in 
mean nutritional status (R’ = 0.84; P < 0.05), for mean length- 
for-age with mean number of episodes/child-year. 
